Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer

• 来源期刊: 亚洲男性学杂志（英文版）
• 年，卷（期）: 2011,（6）
• 页码范围: 785-786
• 页数: 2页
• 语种: 英文
• DOI: 10.1038/aja.2011.113

摘要

In essentially just 1 year's time,we have seen science translated into exciting new therapeutic agents for men with metastatic castration-resistant prostate cancer (CRPC),1 most recently with the United States Food and Drug Administration (FDA) approval of abiraterone acetate in combination with prednisone.2 While prostate cancer has been known to be highly responsive to surgical or medical castration for well over half a century,3 what was once termed 'hormone refractory' prostate cancer inevitably developed,leading to cancerrelated death.Many consider the introduction of chemotherapy for CRPC initially for symptomatic benefit,then with improvements in survival,a substantial step forward.